Vion Pharmaceuticals
Vion was a Yale spin-out whose alkylating agent laromustine reached phase 3 in older patients with acute myeloid leukaemia but was not approved; the company filed for bankruptcy in 2009.
Overview
Vion Pharmaceuticals, founded in 1992 in New Haven, Connecticut, from Yale University research, developed laromustine (Onrigin), a sulfonylhydrazine alkylating agent, for acute myeloid leukaemia in patients unfit for intensive chemotherapy. The FDA declined approval without a randomised trial and Vion filed for Chapter 11 bankruptcy in 2009. Its trials remain on ClinicalTrials.gov under Vion as lead sponsor.
Similar pages
not linked directly; found by shared links- CompanyCyclacel Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanySunesis Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyDelta-Fly Pharma
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.